Cipro iv (ciprofloxacin) is a synthetic antimicrobial agent for intravenous (iv) administration. ciprofloxacin, a fluoroquinolone, is 1 cyclopropyl 6 fluoro 1,4 dihydro 4 oxo 7 (1piperazinyl) 3quinolinecarboxylic acid. its empirical formula is c 17 h 18 fn 3 o 3 and its chemical structure is:. Cipro iv is indicated for treatment of plague, including pneumonic and septicemic plague, due to yersinia pestis (y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Nda 019857 cipro iv fda approved 25 february 2011 2 clinical pharmacology absorption following 60 minute intravenous infusions of 200 mg and 400 mg ciprofloxacin to normal volunteers, the mean maximum serum concentrations achieved were 2.1 and 4.6 µg ml, respectively; the concentrations at 12 hours were 0.1 and 0.2 µg ml, respectively. Ciprofloxacin is a cyp3a4 and cyp1a2 inhibitor. coadministration with ciprofloxacin increased erlotinib exposure by 39% and increased the erlotinib cmax by 17%. ertugliflozin: (moderate) monitor blood glucose carefully when systemic quinolones and antidiabetic agents, including sglt2 inhibitors, are coadministered. Ciprofloxacin may increase the blood sugar lowering effects of the medication glyburide. also watch for symptoms of low blood sugar such as sudden sweating, shaking, fast heartbeat, hunger.